IBM And Spotfire Deliver Integrated Analytic And Data Management Solution For Life Sciences

Alliance Helps Aventis to Speed Drug Discovery Process

Select a topic or year

SAN DIEGO, CA - 25 Jun 2001: IBM and Spotfire, Inc. today announced plans to collaborate to deliver integrated applications and information management solutions that give researchers greater flexibility and speed in analyzing genomic data, identifying new drug candidates and bringing them to market.

The companies also will cooperate in helping pharmaceutical powerhouse Aventis enhance its drug discovery process through the combination of their technologies.

Announced at the BIO 2001 Conference, the partnership couples Spotfire's DecisionSite* eAnalytic* application platform and information interaction experience for optimizing decision making with IBM's back-end information management, data integration and computing infrastructure. Spotfire will optimize its current products and develop future eAnalytic applications for IBM platforms and middleware, including DB2** Universal Database and DiscoveryLink** data integration software.

The life sciences industry is undergoing a massive transformation, one in which computing and software companies are playing a major role in the acceleration of new product development, escalating the demand for computing power. The evolution to this new era of discovery has significant implications for all companies seeking better methods for aggregating, accessing, manipulating and analyzing data.

"The convergence of science, software and computing being experienced by the life sciences industry creates a significant opportunity for organizations to redefine what they expect from their product development processes," said Rock Gnatovich, president of Spotfire. "The directive that we issue to our customers is to not embark on a data integration projects without understanding the analytic needs of their end users. Our partnership with IBM effects a perfect complement for helping customers deploy next-generation technologies to support their discovery goals."

The combination of IBM's data management platform and Spotfire's industry leading decision-making software will allow life sciences organizations to implement discovery solutions that help them create new drugs, therapies and break-through, life-improving products.

"Our alliance with Spotfire gives life sciences researchers a sustainable competitive advantage," said Dr. Caroline Kovac, vice president of IBM Life Sciences. "Companies like Aventis can accelerate their drug discovery process by seamlessly accessing IBM's data integration and management software and Spotfire's powerful analytic tools."

IBM and Spotfire announced today that Aventis will use the combination of Spotfire DecisionSite and IBM DiscoveryLink to advance its entire scientific research and product discovery process. Aventis will use DiscoveryLink to manage and integrate data from multiple biological and chemical databases, along with DecisionSite to allow researchers to easily query those databases and identify new drug targets. With these technologies, the company expects to substantially accelerate its "Drug Innovation and Approval" process, cutting the time involved from 10 to 15 years to as little as six to nine years.

"Since our inception, we have sought ways to escalate our product discovery process and facilitate the interpretation and use of knowledge through the tremendous advancements being made in technology infrastructure and software," said Peter Loupos, Aventis' global head of Drug Innovation and Approval Information Systems. "Our relationships with Spotfire and IBM will help us to realize this goal, converting our latest research into new families of life sciences products and services, the cornerstone of our ongoing success."

Related XML feeds
Topics XML feeds
Business partners
Business partner information including strategic alliances
Services and solutions
Information Management, Lotus, Tivoli, Rational, WebSphere, Open standards, open source